在恶性B细胞中重新编程RIPK3诱导的细胞死亡促进免疫介导的瘤控制
Ruby Alonso1, Zacarias Garcia1, Béatrice Corre1
1Dynamics of Immune Responses Unit, Institut Pasteur, Université de Paris Cité, INSERM U1223, F-75015 Paris, France.
Science advances
|August 15, 2025
概括
研究人员发现了一种新的方法来对抗B细胞癌症,通过重新编程受体相互作用的氨酸/氨酸蛋白激酶3 (RIPK3) 信号. 这一策略增强了对瘤的免疫反应,提供了一个有前途的新治疗途径.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 免疫性细胞死亡,包括亡,可以增强抗瘤免疫反应.
- 与受体相互作用的氨酸/氨酸蛋白激酶3 (RIPK3) 信号传递对于死细胞灭和固体瘤中的免疫激活至关重要.
- 在B细胞恶性瘤中RIPK3操纵的治疗潜力在很大程度上尚未被探索.
研究的目的:
- 研究RIPK3信号传递在B细胞恶性瘤中的作用.
- 开发一种策略来操纵RIPK3活动,以促进B细胞癌症的免疫媒介瘤控制.
主要方法:
- 利用静脉内成像来监测和控制恶性B细胞中的RIPK3信号传递.
- 研究了RIPK3诱导的细胞死亡途径,包括细胞亡和亡.
- 采用组合治疗,包括RIPK3激活,酶抑制和I型干扰素.
主要成果:
- 在B细胞中RIPK3的激活诱导了细胞亡和巨吞,但由于MLKL的表达率低,并没有致死.
- 与I型干扰素和酶抑制剂的同时治疗成功地将RIPK3诱导的细胞死亡重定向到亡.
- 组合疗法证明了对B细胞瘤的显著免疫媒介控制.
结论:
- 重编程RIPK3活动是针对B细胞恶性瘤的可行策略.
- 调节RIPK3信号的组合疗法为增强B细胞癌的抗瘤免疫提供了一个有希望的方法.
更多相关视频
08:22Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production
Published on: May 31, 2020
5.2K
09:15Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
Published on: October 20, 2022
2.4K
相关概念视频
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:31The Intrinsic Apoptotic Pathway
6.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K